阿摩線上測驗
登入
阿摩線上測驗
登入
試卷名稱：110年 - 110 消化系內科專科醫師甄審試題#131326
年份：110年
科目：消化系內科專科醫師
74. 關於 HCC systemic therapy 的敘述下列何者正確？
(1) Systemic chemotherapy with doxorubicin or FOLFOX did not demonstrate survival benefits
(2) Lenvatinib targets VEGFR1-3; fibroblast growth factor receptor (FGFR1-4);platelet-derived growth factor receptor α, RET, and KIT
(3) Cabozantinib is a MET, VEGFR2 and RET inhibitor approved for thyroid,renal cancer and HCC
(4) Ramucirumab is a monoclonal antibody targeting VEGFR 1-3
(5) Progression-free survival is a composite endpoint that includes two types of variables: death and evidence of radiological progression
(A) (1)＋(2)
(B) (1)＋(2)＋(3)
(C) (2)＋(3)＋(4)
(D) (1)＋(2)＋(3)＋(5)
(E) (1)＋(2)＋(3)＋(4)＋(5)
